

# CRONOS

G R O U P

## **CRONOS GROUP INC.**

**Amended and Restated Condensed Interim Unaudited Consolidated Financial Statements**

For the Three Months Ended March 31, 2019 and March 31, 2018

(In thousands of Canadian dollars)

## **Notice to Reader**

Cronos Group Inc. ("**Cronos Group**" or the "**Company**") has restated its unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019, the six months ended June 30, 2019, and the three and nine months ended September 30, 2019, which were previously filed on SEDAR (the "**interim financial statements**"). Subsequent to the original issuance of the interim financial statements, the Audit Committee of the Company's Board of Directors, with the assistance of outside counsel and forensic accountants, conducted a review of certain bulk resin purchases and sales of products through the wholesale channel and the appropriateness of the recognition of the revenue associated with those transactions. As a result of this review, it was concluded that there were accounting errors in the previously filed interim financial statements. In the case of the three months ended March 31, 2019, these accounting errors were due to one wholesale transaction that was inappropriately accounted for as revenue. These errors have been corrected in the amended and restated unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019, the six months ended June 30, 2019, and the three and nine months ended September 30, 2019. See note 27 of the amended and restated unaudited condensed interim consolidated statements for more detail.

**Cronos Group Inc.**  
**Amended and Restated Unaudited Condensed Interim Consolidated Financial Statements**  
**For the three months ended March 31, 2019 and March 31, 2018**

**Table of Contents**

Amended and Restated Unaudited Condensed Interim Consolidated Statements of Financial Position	1
Amended and Restated Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)	2
Amended and Restated Unaudited Condensed Interim Consolidated Statements of Changes in Equity	3
Amended and Restated Unaudited Condensed Interim Consolidated Statements of Cash Flows	4
Notes to the Amended and Restated Unaudited Condensed Interim Consolidated Financial Statements	5

**Cronos Group Inc.**

**Amended and Restated Unaudited Condensed Interim Consolidated Statements of Financial Position**

**As at March 31, 2019 and December 31, 2018**

(in thousands of CDN \$)

	Notes	As at March 31, 2019 (Restated - Note 27)	As at December 31, 2018
<b>Assets</b>			
Current assets			
Cash and cash equivalents	22(a)	\$ 2,418,277	\$ 32,634
Interest receivable	22(a)	3,130	-
Accounts receivable	22(a)	2,761	4,163
Sales taxes receivable		5,240	3,419
Prepaid expenses and other assets		5,092	4,190
Biological assets	5	11,506	9,074
Inventory	5	25,082	11,584
Total current assets		<u>2,471,088</u>	<u>65,064</u>
Advances to joint ventures	6(a)	21,920	6,395
Net investments in equity accounted investees	6(b)	2,185	4,038
Other investments	7,22(c)	300	705
Property, plant and equipment	8	184,570	171,720
Right-of-use assets	3(a),11(a)	1,875	171
Intangible assets	9(a)	11,087	11,234
Goodwill	9(b)	1,792	1,792
<b>Total assets</b>		<u>\$ 2,694,817</u>	<u>\$ 261,119</u>
<b>Liabilities</b>			
Current liabilities			
Bank indebtedness	22(b)	\$ 422	\$ -
Accounts payable and other liabilities	22(b)	41,896	15,372
Holdbacks payable	22(b)	8,482	7,887
Government remittances payable	22(b)	1,313	1,123
Current portion of lease obligations	11,22(b)	134	41
Derivative liabilities	13,22(b)	1,664,275	-
Construction loan payable	12,22(b)	-	20,951
Total current liabilities		<u>1,716,522</u>	<u>45,374</u>
Lease obligations	11,22(b)	1,827	119
Due to non-controlling interests	10,22(b)	2,247	2,136
Deferred income tax liability	20	3,996	1,850
Total liabilities		<u>1,724,592</u>	<u>49,479</u>
<b>Shareholders' equity</b>			
Share capital	14(a)	556,930	225,500
Warrants	15(a)	845	1,548
Stock options	15(b)	6,631	6,241
Retained earnings (accumulated deficit)		404,774	(22,715)
Accumulated other comprehensive income		1,049	930
Total equity attributable to shareholders of Cronos Group		<u>970,229</u>	<u>211,504</u>
Non-controlling interests	10	(4)	136
Total shareholders' equity		<u>970,225</u>	<u>211,640</u>
<b>Total liabilities and shareholders' equity</b>		<u>\$ 2,694,817</u>	<u>\$ 261,119</u>
Commitments and contingencies	19		
Subsequent events	25		

The accompanying notes are an integral part of these amended and restated unaudited condensed interim consolidated financial statements

Approved on behalf of the Board of Directors:

*"Michael Gorenstein"*

Director

*"James Rudyk"*

Director

**Cronos Group Inc.**

**Amended and Restated Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss)**

**For the three months ended March 31, 2019 and March 31, 2018**

*(in thousands of CDN \$, except share and per share amounts)*

	Notes	Three Months Ended March 31,	
		2019 (Restated - Note 27)	2018
<b>Gross revenue</b>	16	\$ 4,509	\$ 2,945
Excise taxes		(515)	-
<b>Net revenue</b>		3,994	2,945
<b>Cost of sales</b>			
Cost of sales before fair value adjustments	4(b)	1,927	1,567
<b>Gross profit before fair value adjustments</b>		2,067	1,378
<b>Fair value adjustments</b>			
Unrealized change in fair value of biological assets	4(b)	(13,553)	(2,744)
Realized fair value adjustments on inventory sold in the period	4(b)	2,403	2,194
Total fair value adjustments		(11,150)	(550)
<b>Gross profit</b>		13,217	1,928
<b>Operating expenses</b>			
Sales and marketing		1,500	586
Research and development		1,557	-
General and administrative		9,611	2,461
Share-based payments	15(b),18	737	774
Depreciation and amortization	8,9(a),11(a)	470	285
Total operating expenses		13,875	4,106
<b>Operating loss</b>		(658)	(2,178)
<b>Other income (expense)</b>			
Interest income (expense)		2,720	(22)
Financing costs	12,13	(29,561)	-
Gain on revaluation of derivative liabilities	13	436,383	-
Share of income (loss) from investments in equity accounted investees	6	(264)	41
Gain on disposal of Whistler	6	20,606	-
Gain on other investments	7	924	221
Total other income		430,808	240
Income (loss) before income taxes		430,150	(1,938)
Deferred income tax expense (recovery)	20	2,182	(888)
<b>Net income (loss)</b>		\$ 427,968	\$ (1,050)
<b>Net income (loss) attributable to:</b>			
Cronos Group		\$ 428,104	\$ (1,050)
Non-controlling interests	10	(136)	-
		\$ 427,968	\$ (1,050)
<b>Other comprehensive income (loss)</b>			
Gain (loss) on revaluation and disposal of other investments, net of tax	7,20	\$ 103	\$ (35)
Foreign exchange gain on translation of foreign operations	2(d),10	16	-
Total other comprehensive income (loss)		119	(35)
<b>Comprehensive income (loss)</b>		\$ 428,087	\$ (1,085)
<b>Comprehensive income (loss) attributable to:</b>			
Cronos Group		\$ 428,223	\$ (1,085)
Non-controlling interests	10	(136)	-
		\$ 428,087	\$ (1,085)
<b>Earnings (loss) per share</b>			
Basic	17	\$ 1.96	\$ (0.01)
Diluted	17	\$ 0.48	\$ (0.01)
<b>Weighted average number of outstanding shares</b>			
Basic	17	218,949,590	157,054,891
Diluted	17	271,086,575	157,054,891

The accompanying notes are an integral part of these amended and restated unaudited condensed interim consolidated financial statements

**Cronos Group Inc.**

**Amended and Restated Unaudited Condensed Interim Consolidated Statements of Changes in Equity**

**For the three months ended March 31, 2019 and March 31, 2018**

*(in thousands of CDN \$, except number of share amounts)*

	Notes	Number of shares	Share capital	Shares to be issued	Share-based reserve		Retained earnings (accumulated deficit) (Restated - Note 27)	Accumulated other comprehensive income	Non-controlling interests	Total (Restated - Note 27)
					Warrants	Stock options				
Balance at January 1, 2019 as previously reported		178,720,022	\$ 225,500	\$ -	\$ 1,548	\$ 6,241	\$ (22,715)	\$ 930	\$ 136	\$ 211,640
Adoption of IFRS 16	3(a)	-	-	-	-	-	(68)	-	(4)	(72)
Balance at January 1, 2019 as restated		178,720,022	225,500	-	1,548	6,241	(22,783)	930	132	211,568
Shares issued	14(a)	149,831,154	334,099	-	-	-	-	-	-	334,099
Share issuance costs		-	(4,901)	-	-	-	-	-	-	(4,901)
Warrants exercised	15(a)	4,390,961	1,884	-	(703)	-	-	-	-	1,181
Vesting of options	15(b)	-	-	-	-	737	-	-	-	737
Options exercised	15(b)	375	2	-	-	(1)	-	-	-	1
Share appreciation rights exercised	15(b)	77,865	346	-	-	(346)	(547)	-	-	(547)
Net income (loss)		-	-	-	-	-	428,104	-	(136)	427,968
Other comprehensive income		-	-	-	-	-	-	119	-	119
Balance at March 31, 2019		<u>333,020,377</u>	<u>\$ 556,930</u>	<u>\$ -</u>	<u>\$ 845</u>	<u>\$ 6,631</u>	<u>\$ 404,774</u>	<u>\$ 1,049</u>	<u>\$ (4)</u>	<u>\$ 970,225</u>
Balance at January 1, 2018		149,360,603	\$ 83,559	\$ -	\$ 3,364	\$ 2,289	\$ (3,724)	\$ 880	\$ -	\$ 86,368
Shares issued	14(a)	5,257,143	46,000	-	-	-	-	-	-	46,000
Share issuance costs		-	(3,081)	-	-	-	-	-	-	(3,081)
Shares to be issued	14(b)	-	-	961	-	-	-	-	-	961
Warrants exercised	15(a)	6,972,479	1,966	-	(686)	-	-	-	-	1,280
Vesting of options	15(b)	-	-	-	-	774	-	-	-	774
Options exercised	15(b)	42,256	106	-	-	(33)	-	-	-	73
Net loss		-	-	-	-	-	(1,050)	-	-	(1,050)
Other comprehensive loss		-	-	-	-	-	-	(35)	-	(35)
Balance at March 31, 2018		<u>161,632,481</u>	<u>\$ 128,550</u>	<u>\$ 961</u>	<u>\$ 2,678</u>	<u>\$ 3,030</u>	<u>\$ (4,774)</u>	<u>\$ 845</u>	<u>\$ -</u>	<u>\$ 131,290</u>

The accompanying notes are an integral part of these amended and restated unaudited condensed interim consolidated financial statements

**Cronos Group Inc.**

**Amended and Restated Unaudited Condensed Interim Consolidated Statements of Cash Flows**

**For the three months ended March 31, 2019 and March 31, 2018**

*(in thousands of CDN \$)*

	Notes	Three Months Ended March 31,	
		2019 (Restated - Note 27)	2018
<b>Operating activities</b>			
Net income (loss)		\$ 427,968	\$ (1,050)
Items not affecting cash and cash equivalents:			
Unrealized change in fair value of biological assets	4(b)	(13,553)	(2,744)
Realized fair value adjustments on inventory sold in the period	4(b)	2,403	2,194
Share-based payments	15(b),18	737	774
Depreciation and amortization	8,9(a),11(a)	470	285
Depreciation relieved on inventory sold		235	169
Share of loss (income) from investments in equity accounted investees	6	264	(41)
Gain on disposal of Whistler	6	(20,606)	-
Gain on other investments	7	(924)	(221)
Gain on revaluation of derivative liabilities	13	(436,383)	-
Deferred income tax expense (recovery)	20	2,182	(888)
Foreign exchange loss (gain)		67	(16)
Net changes in non-cash working capital	21	18,739	(12,212)
Cash and cash equivalents used in operating activities		(18,401)	(13,750)
<b>Investing activities</b>			
Investments in equity accounted investees	6	(2,200)	-
Advances to joint ventures	6	(15,812)	-
Proceeds from sale of other investments	7	26,078	687
Payment to exercise ABCann warrants	7	-	(113)
Purchase of property, plant and equipment	8	(13,454)	(7,642)
Purchase of intangible assets	9(a)	(51)	(131)
Advance to Cronos Israel	2(a),10	-	(926)
Cash and cash equivalents used in investing activities		(5,439)	(8,125)
<b>Financing activities</b>			
Increase in bank indebtedness		422	-
Advance from non-controlling interests	10	111	-
Repayment of lease obligations	11	(32)	(13)
Repayment of construction loan payable	12	(21,311)	-
Payment of accrued interest on construction loan payable	12	(121)	(185)
Advance under Credit Facility	12	65,000	-
Repayment of Credit Facility	12	(65,000)	-
Proceeds from Altria Investment	13,14(a)	2,434,757	-
Proceeds from share issuance	14(a)	-	46,000
Share issuance costs		(4,901)	(3,081)
Proceeds from shares to be issued	14(b)	-	961
Proceeds from exercise of warrants and options	15(a),(b)	1,182	1,353
Withholding taxes paid on share appreciation rights	15(b)	(547)	-
Cash and cash equivalents provided by financing activities		2,409,560	45,035
Net change in cash and cash equivalents		2,385,720	23,160
Cash and cash equivalents - beginning of period		32,634	9,208
Effects of foreign exchange on cash		(77)	-
<b>Cash and cash equivalents - end of period</b>		<b>\$ 2,418,277</b>	<b>\$ 32,368</b>
<b>Supplemental cash flow information</b>			
Interest paid		\$ 675	\$ 307

The accompanying notes are an integral part of these amended and restated unaudited condensed interim consolidated financial statements

## 1. Nature of business

Cronos Group Inc. ("**Cronos Group**" or the "**Company**") was incorporated under the *Business Corporations Act* (Ontario). Cronos Group is a public corporation, with its head office located at 720 King Street West, Suite 320, Toronto, Ontario, M5V 2T3. The Company's common shares are listed on the Nasdaq Global Market and on the Toronto Stock Exchange ("**TSX**") under the ticker symbol ("**CRON**").

Cronos Group is an innovative global cannabinoid company, with international production and distribution across five continents. The Company is engaged in the cultivation, manufacturing, and marketing of cannabis and cannabis-derived products for the medical and adult-use markets. Cronos Group is committed to building disruptive intellectual property by advancing cannabis research, technology and product development. With a passion to responsibly elevate the consumer experience, Cronos Group is building an iconic brand portfolio. Cronos Group's brand portfolio includes PEACE NATURALS™, a global health and wellness brand, and two adult-use brands, COVE™ and Spinach™. The Company operates two wholly-owned license holders ("**License Holders**") under the *Cannabis Act* (Canada) and its relevant regulations (the "**Cannabis Act**"). The Company's License Holders are Peace Naturals Project Inc. ("**Peace Naturals**"), which has production facilities near Stayner, Ontario, and Original BC Ltd. ("**OGBC**"), which has a production facility in Armstrong, British Columbia.

Cronos Group has also established five strategic joint ventures in Canada, Israel, Australia, and Colombia, and holds minority interests in cannabis-related companies and License Holders. One of these strategic joint ventures is considered a subsidiary for financial reporting purposes, refer to Note 2(a).

## 2. Basis of presentation

These amended and restated unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019 and March 31, 2018 have been prepared in accordance with International Accounting Standard ("**IAS**") 34, Interim Financial Reporting. The accounting policies adopted in the preparation of the amended and restated unaudited condensed interim consolidated financial statements are consistent with those followed in the preparation of the Company's audited annual consolidated financial statements for the year ended December 31, 2018, except for the adoption of new standards effective as of January 1, 2019. The Company has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. The Company applied, as of January 1, 2019, International Financial Reporting Standard ("**IFRS**") 16, Leases and Interpretation of the IFRS Interpretations Committee ("**IFRIC**") 23, Uncertainty over income tax treatments. As required by IAS 34, the nature and effect of these changes are disclosed in Note 3.

These amended and restated unaudited condensed interim consolidated financial statements do not conform in all respects to the requirements of IFRS as issued by the International Accounting Standards Board for annual financial statements. Accordingly, these amended and restated unaudited condensed interim consolidated financial statements should be read in conjunction with the Company's December 31, 2018 audited annual consolidated financial statements and notes.

These amended and restated unaudited condensed interim consolidated financial statements were approved by the Board of Directors (the "**Board**") on March 29, 2020.



## 2. Basis of presentation (continued)

### (a) Basis of consolidation

These amended and restated unaudited condensed interim consolidated financial statements include the accounts of Cronos Group Inc. and its subsidiaries, summarized in the following chart:

Subsidiaries	Jurisdiction of incorporation	Incorporation date	Ownership interest
Hortican Inc. (" <b>Hortican</b> ")	Canada	January 17, 2013	100%
Peace Naturals	Canada	November 21, 2012	100%
OGBC	Canada	March 15, 2013	100%
Cronos Canada Holdings Inc.	Canada	March 13, 2018	100%
Cronos Global Holdings Inc.	Canada	April 25, 2017	100%
Cronos Israel G.S. Cultivations Ltd. <sup>(i)</sup>	Israel	February 4, 2018	70%
Cronos Israel G.S. Manufacturing Ltd. <sup>(i)</sup>	Israel	September 4, 2018	90%
Cronos Israel G.S. Store Ltd. <sup>(i)</sup>	Israel	June 28, 2018	90%
Cronos Israel G.S. Pharmacies Ltd. <sup>(i)</sup>	Israel	February 15, 2018	90%
Cronos Labs Ltd. (" <b>Cronos Device Labs</b> ")	Israel	March 14, 2019	100%
Cronos Group Celtic Holdings Ltd.	Ireland	February 6, 2018	100%
Cronos Malta Holdings Ltd.	Malta	October 25, 2018	100%

<sup>(i)</sup> These Israeli entities are collectively referred to as "**Cronos Israel**".

In the amended and restated unaudited condensed interim consolidated statements of operations and comprehensive income (loss), net income (loss) and other comprehensive income (loss) are attributed to the equity holders of the Company and to the non-controlling interests. Non-controlling interests in the equity of Cronos Israel are presented separately in the shareholders' equity section of the amended and restated unaudited condensed interim consolidated statements of financial position and the amended and restated unaudited condensed interim consolidated statements of changes in equity.

### (b) Investments in equity accounted investees

Investees in which the Company has significant influence or joint control are accounted for using the equity method. The Company's interests in equity accounted investees as at March 31, 2019 are summarized in the following chart.

Equity accounted investees	Jurisdiction of incorporation	Ownership interest
Cronos Australia Limited (" <b>Cronos Australia</b> ")	Australia	50%
MedMen Canada Inc. (" <b>MedMen Canada</b> ")	Canada	50%
Cronos Growing Company Inc. (" <b>Cronos GrowCo</b> ")	Canada	50%
NatuEra S.à r.l	Luxembourg	50%

As at December 31, 2018, the Company held a 19% ownership interest in Whistler Medical Marijuana Company ("**Whistler**"). During the three months ended March 31, 2019, the Company divested of its investment in Whistler.

### (c) Basis of measurement

Apart from biological assets, other investments, and derivative liabilities, which are measured at fair value, the amended and restated unaudited condensed interim consolidated financial statements have been presented and prepared on the basis of historical cost.

## 2. Basis of presentation (continued)

### (d) Functional and presentation currency

These amended and restated unaudited condensed interim consolidated financial statements are presented in Canadian dollars, which is the functional currency of the Company. The functional currency of all subsidiaries is the national currency of the respective jurisdiction of incorporation. Refer to Note 2(a).

## 3. Adoption of new accounting pronouncements

### (a) IFRS 16, Leases

IFRS 16 was issued in January 2016 and replaces the previous guidance on leases, predominantly IAS 17, Leases. The Company has applied IFRS 16 with an initial application date of January 1, 2019, in accordance with the transitional provisions specified in IFRS 16. As a result, the Company has changed its accounting policy for lease contracts as detailed below. The Company has applied the following practical expedients:

- (i) The Company applied the simplified transition approach and did not restate comparative information. As a result, the Company recognized the cumulative effect of initially applying IFRS 16 as an adjustment to the accumulated deficit as at January 1, 2019.
- (ii) On transition to IFRS 16, the Company elected to apply the practical expedient to grandfather the assessment of which transactions are leases. The Company applied IFRS 16 only to contracts that were previously identified as leases. Contracts that were not identified as leases under IAS 17, and IFRIC 4, Determining whether an arrangement contains a lease, were not reassessed for whether there is a lease. The Company applied the definition of a lease under IFRS 16 to contracts entered into or changed on or after January 1, 2019.

In accordance with the practical expedients applied, the Company has recognized lease liabilities and right-of-use assets at the date of initial application for leases previously classified as operating leases in accordance with IAS 17. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company has elected to measure the right-of-use assets at the carrying amount as if IFRS 16 had been applied since the commencement date, discounted using the Company's incremental borrowing rate at the date of initial application. For the lease previously classified as a finance lease under IAS 17, the carrying amount of the right-of-use asset and the lease liability at the date of initial application is equal to the carrying amount of the leased asset and lease liability immediately before the date of initial application.

The following table summarizes the impacts of adopting IFRS 16 on the Company's amended and restated unaudited condensed interim consolidated financial statements as at the date of initial application:

As at January 1, 2019	As previously reported under IAS 17		Adjustments <sup>(i)</sup>		As restated under IFRS 16
Right-of-use assets	\$	217	\$	1,890	\$ 2,107
Accumulated depreciation		46		144	190
Current lease liabilities		41		303	344
Non-current lease liabilities		119		1,515	1,634
Accumulated deficit		(22,715)		(68)	(22,783)
Non-controlling interests		136		(4)	132

- (i) The adjustments are due to the recognition of right-of-use assets and lease obligations for lease contracts previously classified as operating leases under IAS 17 prior to the date of initial application. The weighted average incremental borrowing rate applied to the lease liabilities recognized at the date of initial application is 12%. There would be no difference between the discounted value of the operating lease commitments disclosed at December 31, 2018 and the adjustments above. Furthermore, there were no onerous lease contracts that would have required an adjustment to the right-of-use assets at the date of initial application.

---

### 3. Adoption of new accounting pronouncements (continued)

#### (a) IFRS 16, Leases (continued)

The following is the Company's policy for accounting for lease contracts in accordance with IFRS 16:

At the inception of a contract, the Company assesses whether a contract is, or contains, a lease. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. The Company recognizes a right-of-use asset and a lease liability at the commencement date of the lease. The right-of-use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset, less any lease incentives received. The right-of-use asset is subsequently depreciated using the straight-line method from the commencement date to the earlier of the end of the useful life of the right-of-use asset or the end of the lease term. In addition, the right-of-use assets are adjusted for impairment losses, if any. The estimated useful lives and recoverable amounts of right-of-use assets are determined on the same basis as those of property and equipment. The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted using the interest rate implicit in the lease or, if that rate cannot be readily determined, the Company's incremental borrowing rate. The lease liability is subsequently measured at amortized cost using the effective interest method. The Company has elected not to recognize right-of-use assets and lease liabilities for short-term leases (lease term of 12 months or less) and leases for which the underlying asset is of low value. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

#### (b) IFRIC 23, Uncertainty over income tax treatments

IFRIC 23 clarifies the application of recognition and measurement requirements in IAS 12, Income taxes, when there is uncertainty over income tax treatments. It specifically addresses whether an entity considers each tax treatment independently or collectively, the assumptions an entity makes about the examination of tax treatments by taxation authorities, how an entity determines taxable profit (tax loss), tax bases, unused tax losses, unused tax credits and tax rates, and how an entity considers changes in facts and circumstances. IFRIC 23 became effective for fiscal years beginning on or after January 1, 2019, with earlier application permitted. The Company has adopted this interpretation as of its effective date and has assessed no significant impact as a result of the adoption of this interpretation.

### 4. Accounting changes

#### (a) Change in estimate

During the three months ended March 31, 2018, the Company revised its estimate of the useful life of the Health Canada licenses, and assessed that the licenses have an estimated useful life equal to the remaining useful life of the corresponding facilities described in Note 9(a). Previously, the Company estimated that the Health Canada Licenses had an indefinite life. The change in estimate was accounted for prospectively.

#### (b) Change in accounting policy

During the three months ended June 30, 2018, the Company made a voluntary change in accounting policy to capitalize the direct and indirect costs attributable to the biological asset transformation. The previous accounting policy was to expense these costs as period costs.

The new accounting policy provides more reliable and relevant information to users as the gross profit before fair value adjustments only considers the costs incurred on inventory sold during the period, and excludes costs incurred on the biological transformation until the related harvest is sold. The following demonstrates the change for each prior period presented. There is no impact of this policy change on gross profit, net income (loss), basic and diluted earnings per share, the amended and restated unaudited condensed interim consolidated statement of financial position, or the amended and restated unaudited condensed interim consolidated statement of changes in equity on the current or any prior period, upon retrospective application

**4. Accounting changes (continued)**

	Three Months Ended March 31, 2019		Three Months Ended March 31, 2018	
	Original accounting policy (Restated - Note 27)	New accounting policy (Restated - Note 27)	Original accounting policy	New accounting policy
<b><i>Amended and restated unaudited condensed interim consolidated statement of operations and comprehensive income (loss)</i></b>				
<b>Cost of sales</b>				
Cost of sales before fair value adjustments	\$ 627	\$ 1,927	\$ 521	\$ 1,567
Production costs	3,338	-	1,714	-
Total cost of sales	3,965	1,927	2,235	1,567
<b>Gross profit before fair value adjustments</b>	29	2,067	710	1,378
Fair value adjustments:				
Unrealized change in fair value of biological assets	(16,891)	(13,553)	(4,458)	(2,744)
Realized fair value adjustments on inventory sold in the period	3,703	2,403	3,240	2,194
Total fair value adjustments	(13,188)	(11,150)	(1,218)	(550)
<b>Gross profit</b>	<u>\$ 13,217</u>	<u>\$ 13,217</u>	<u>\$ 1,928</u>	<u>\$ 1,928</u>

	Three Months Ended March 31, 2019		Three Months Ended March 31, 2018	
	Original accounting policy (Restated - Note 27)	New accounting policy (Restated - Note 27)	Original accounting policy	New accounting policy
<b><i>Amended and restated unaudited condensed interim consolidated statement of cash flows</i></b>				
<b>Operating activities</b>				
Items not affecting cash:				
Unrealized change in fair value of biological assets	\$ (16,891)	\$ (13,553)	\$ (4,458)	\$ (2,744)
Realized fair value adjustments on inventory sold in the period	3,703	2,403	3,240	2,194
Net changes in non-cash working capital:				
Biological assets	15,033	11,695	3,740	2,026
Inventory	(17,144)	(15,814)	(3,802)	(2,756)
<b>Net effect on cash flows used in operating activities</b>	<u>\$ (15,269)</u>	<u>\$ (15,269)</u>	<u>\$ (1,280)</u>	<u>\$ (1,280)</u>

**5. Biological assets and inventory**

## (a) Biological assets

The Company's biological assets consist of cannabis plants. The changes in the carrying amounts of the biological assets are as follows:

**5. Biological assets and inventory (continued)**

	Three Months Ended March 31,	
	2019 (Note 4)	2018 (Note 4)
Biological assets - beginning of period	\$ 9,074	\$ 3,722
Capitalization of production costs	3,338	1,714
Unrealized change in fair value of biological assets	13,553	2,744
Transferred to inventory upon harvest	(14,459)	(3,690)
Biological assets - end of period	<u>\$ 11,506</u>	<u>\$ 4,490</u>

As at March 31, 2019, the Company has 67,635 plants classified as biological assets which are expected to ultimately yield 6,155 kg of dry cannabis (December 31, 2018 - 46,004 plants which were expected to ultimately yield 6,303 kg of dry cannabis).

The Company measures its biological assets at fair value less costs to sell. This valuation is based on the expected harvest yield (on a grams per plant basis) for plants currently being cultivated, adjusted for the expected net selling price less post-harvest costs attributable to bringing a harvested gram of cannabis to a saleable condition and ultimate sale (on a per gram basis). The Company accretes the fair value of each cannabis plant on a straight-line basis over the expected growing cycle. As at March 31, 2019, the plants were on average 5 weeks into the growing cycle, 38% complete, and were ascribed approximately 38% (December 31, 2018 - 6 weeks, 37%, and 37%, respectively) of their expected fair value at harvest date.

## (b) Inventory

Inventory consisted of the following:

	As at March 31, 2019 (Restated - Note 27)		As at December 31, 2018	
<b>Dry cannabis</b>				
Finished goods	181 kg	\$ 1,014	187 kg	\$ 972
Work-in-process	3,261 kg	18,878	1,789 kg	7,733
		<u>19,892</u>		<u>8,705</u>
<b>Cannabis oils<sup>(i)</sup></b>				
Finished goods	200 kg	1,054	115 kg	656
Work-in-process	1,175 kg	2,648	220 kg	1,250
		<u>3,702</u>		<u>1,906</u>
<b>Raw materials<sup>(ii)</sup></b>		169		171
Supplies and consumables		1,319		802
		<u>\$ 25,082</u>		<u>\$ 11,584</u>

<sup>(i)</sup> Cannabis oils are expressed in dry cannabis gram equivalents. Refer to Note 5(d) for the equivalency factor applied.

<sup>(ii)</sup> As at March 31, 2019 and December 31, 2018, raw materials consisted of 0.267 kg of seeds held by the Company.

As at March 31, 2019, the Company held 40 kg (December 31, 2018 - 29 kg) of dry cannabis and 5 kg (December 31, 2018 - 4 kg) of cannabis oils as retention samples, which are valued at \$nil.

**5. Biological assets and inventory (continued)****(c) Direct and indirect cost allocations**

Costs incurred to transform biological assets up to the point of harvest ("**production costs**") are capitalized as they are incurred, which become the cost basis of the biological assets. These costs include direct costs such as nutrients, soil, and seeds, as well as other indirect costs such as utilities, an allocation of indirect labour, property taxes, and depreciation of equipment used in the growing process. The biological assets are then revalued to fair value less costs to sell immediately prior to harvest and at the end of each reporting period. Gains or losses arising from changes in fair value less costs to sell, excluding capitalized production costs, are presented as unrealized change in fair value of biological assets. At the point of harvest, agricultural produce consisting of cannabis is considered inventory. The fair value less costs to sell becomes the cost base of inventory. Any subsequent post-harvest costs ("**processing costs**"), including direct costs attributable to processing and related overhead, are capitalized to inventory as they are incurred. Upon ultimate sale of inventory, the associated production and processing costs are presented as cost of sales before fair value adjustments; the remaining cost of inventory, associated with fair value less costs to sell prior to harvest, is presented as realized fair value adjustments on inventory sold in the period.

The direct and indirect costs related to biological assets and inventory are allocated as follows. The allocation basis was consistent for the three months ended March 31, 2019 and 2018, unless otherwise specified.

Nature of cost	Allocation basis
Consumables (insect control, fertilizers, soil)	100% allocated to production costs because these costs are incurred to support plant growth
Labour costs (including salaries and benefits)	Allocated based on job descriptions of various personnel 40% allocated to processing costs; 40% allocated to production costs; 20% allocated to operating expenses (2018 - 20%; 60%; and 20%; respectively)
Supplies and small tools	80% allocated to production costs; 20% allocated to processing costs
Utilities	Allocated based on estimates of usage 10% allocated to processing costs; 90% allocated to production costs
Property taxes, depreciation, security	Allocated based on estimates of square footage 20% allocated to processing costs; 50% allocated to production costs; 30% allocated to operating expenses
Packaging costs	100% allocated to processing costs

**(d) Significant inputs and sensitivity analyses**

The Company has made the following estimates related to significant inputs in the valuation model:

Significant inputs	Definition
Net selling price per gram	Estimated net selling price per gram of dry cannabis based on historical sales and anticipated prices, after adjustment for excise taxes
Harvest yield per plant	Expected grams of dry cannabis to be harvested from a cannabis plant, based on the weighted average historical yields by plant strain
Stage of growth	Weighted average plant age (in weeks) out of the 14 week (December 31, 2018 - 16 week) growing cycle as of the period end date
Processing costs per gram	Estimated post-harvest costs per gram to bring a gram of harvested cannabis to its saleable condition, including drying, curing, testing and packaging, and overhead allocation; estimated based on post-harvest costs incurred during the period divided by number of grams processed during the period
Selling costs per gram	Estimated shipping, order fulfillment, and labelling costs per gram; calculated as selling costs incurred during the period divided by number of grams sold during the period
Equivalency factor	Estimated grams of dry cannabis required to produce one millilitre of cannabis oil; estimated based on historical conversion results
Mass multipliers	Estimated multiples of crude extract and isolate mass in diluted cannabis oil products

**5. Biological assets and inventory (continued)**

## (d) Significant inputs and sensitivity analyses (continued)

These inputs are level 3 on the fair value hierarchy, and are subject to volatility and several uncontrollable factors, which could significantly affect the fair value of biological assets and inventory in future periods.

The following table quantifies each of the significant unobservable inputs described above and provides a sensitivity analysis of the impact on the reported values of biological assets and inventory. The sensitivity analysis for each significant input is performed by assuming a 5% decrease in the input while other significant inputs remain constant at management's best estimate as of the period end date.

	As at March 31, 2019	Increase (decrease) as at March 31, 2019		As at December 31, 2018	Increase (decrease) as at December 31, 2018	
		Biological assets	Inventory		Biological assets	Inventory
Net selling price per gram	\$5.97/g	\$ (708)	\$ (705)	\$5.58/g	\$ (673)	\$ (640)
Harvest yield per plant	91 g	(572)	-	137 g	(446)	-
Stage of growth	5 weeks	(572)	-	6 weeks	(446)	-
Processing costs per gram	\$0.76/g	90	83	\$1.98/g	175	65
Selling costs per gram	\$0.40/g	47	47	\$0.43/g	52	50
Equivalency factor	0.3 g/mL	(48)	(138)	0.3 g/mL	(45)	(104)
Mass multipliers	35x - 50x	(35)	(222)	30x - 50x	(5)	(24)

**6. Equity accounted investees**

## (a) Advances to joint ventures

Advances to joint ventures are unsecured, non-interest bearing, and have no terms of repayment, unless otherwise specified. The joint ventures are solely funded by their shareholders and the advances are considered an extension of the Company's investments therein. As such, losses recognized in excess of the Company's capital contributions are applied against the respective advances.

As at March 31, 2019	Natuera Colombia <sup>(v)</sup>	MedMen Canada <sup>(ii)</sup>	Cronos GrowCo <sup>(iii)</sup>	Cronos Australia <sup>(iv)</sup>	Total
Gross advances to joint ventures	\$ 302	\$ 1,856	\$ 19,115	\$ 1,480	\$ 22,753
Less: advances to joint ventures applied to carrying amount of investments	-	(167)	-	(666)	(833)
Advances to joint ventures	\$ 302	\$ 1,689	\$ 19,115	\$ 814	\$ 21,920
As at December 31, 2018	Natuera Colombia <sup>(v)</sup>	MedMen Canada <sup>(ii)</sup>	Cronos GrowCo <sup>(iii)</sup>	Cronos Australia <sup>(iv)</sup>	Total
Gross advances to joint ventures	\$ -	\$ 1,871	\$ 4,080	\$ 990	\$ 6,941
Less: advances to joint ventures applied to carrying amount of investments	-	(175)	(29)	(342)	(546)
Advances to joint ventures	\$ -	\$ 1,696	\$ 4,051	\$ 648	\$ 6,395

The Company did not make any advances to its joint ventures during the three months ended March 31, 2018.

**6. Equity accounted investees (continued)**

## (b) Net investment in equity accounted investees

A reconciliation of the carrying amount of the investments in associates and joint ventures is as follows:

	Whistler <sup>(i)</sup>	MedMen Canada <sup>(ii)</sup>	Cronos GrowCo <sup>(iii)</sup>	Cronos Australia <sup>(iv)</sup>	Total
As at January 1, 2019	\$ 4,038	\$ -	\$ -	\$ -	\$ 4,038
Share of net income (loss)	38	8	14	(324)	(264)
Contribution to (disposal of) investment	(4,076)	-	2,200	-	(1,876)
Advances to joint ventures applied to (transferred from) carrying amount of investments	-	(8)	(29)	324	287
As at March 31, 2019	\$ -	\$ -	\$ 2,185	\$ -	\$ 2,185
	Whistler <sup>(i)</sup>	MedMen Canada <sup>(ii)</sup>	Cronos GrowCo <sup>(iii)</sup>	Cronos Australia <sup>(iv)</sup>	Total
As at January 1, 2018	\$ 3,807	\$ -	\$ -	\$ -	\$ 3,807
Share of net income	41	-	-	-	41
As at March 31, 2018	\$ 3,848	\$ -	\$ -	\$ -	\$ 3,848

(i) Whistler was incorporated in British Columbia, Canada and is a License Holder with production facilities in British Columbia, Canada. Although the Company held less than 20% of the ownership interest and voting control of Whistler as at December 31, 2018, the Company had the ability to exercise significant influence through both its power to elect board members, and aggregately, with affiliated shareholders, the Company held over 20% of the voting control of Whistler.

On March 4, 2019, the Company sold all 2,563 shares of Whistler, representing approximately 19.0% of Whistler's issued and outstanding common shares, to Aurora Cannabis Inc. ("**Aurora**"), in connection with Aurora's acquisition of Whistler (the "**Whistler Transaction**"). As a result of the closing of the Whistler Transaction, the Company received 2,524,341 Aurora common shares with an aggregate value of approximately \$24,682. The closing of the Whistler Transaction resulted in a gain of \$20,606 recognized in net income, with the Aurora common shares received being measured at fair value through profit or loss. Refer to Note 7. In addition, the Company expects to further receive Aurora common shares valued at an aggregate of approximately \$7,600 upon the satisfaction of certain specified milestones, which has not been recognized in these amended and restated unaudited condensed interim consolidated financial statements. The exact number of Aurora common shares to be issued to the Company following the satisfaction of each such milestone will be determined in reference to the five-day volume weighted average price of Aurora common shares immediately prior to the achievement of the applicable milestone.

(ii) MedMen Canada was incorporated under the *Canada Business Corporations Act* ("**CBCA**") on March 13, 2018, with the objective of distribution, sale, and marketing of cannabis products in Canada. MedMen Canada holds the exclusive license to the MedMen brand in Canada for a minimum term of 20 years, commencing from 2018.

(iii) Cronos GrowCo was incorporated under the CBCA on June 14, 2018, with the objective of building a cannabis production greenhouse, applying for cannabis licenses under the Cannabis Act, and growing, cultivating, extracting, producing, selling, and distributing cannabis in accordance with such licenses.

(iv) Cronos Australia Pty. Ltd. was incorporated under the Corporations Act 2001 (Australia) on December 6, 2016. On September 27, 2018, Cronos Australia Pty. Ltd. underwent a restructuring, resulting in the incorporation of Cronos Australia Limited on that date, which became the ultimate holding company of the group, owning 100% of Cronos Australia Group Pty. Ltd., which in turn owns 100% of Cronos Australia - Marketing & Distribution Pty. Ltd., Cronos Australia - Operations Pty. Ltd, and Cronos Australia - New Zealand Ltd. Cronos Group has committed to provide 50% of the capital expenditure and operating expense funding requirements, amounting to approximately \$10,000. The timing of these funding obligations has not been determined as of March 31, 2019.



**6. Equity accounted investees (continued)**

Advances are denominated in Australian dollars ("**AUD**"). \$1,480 (\$1,500 AUD) (December 31, 2018 - \$940 (\$1,000 AUD)) is governed by an unsecured loan bearing interest at a rate of 12% per annum, calculated and compounded daily, in arrears, on the amounts advanced from the date of each advance. The loan is due at the earlier of Cronos Australia's initial public offering date and December 1, 2020. If the loan is overdue, the outstanding amount bears interest at an additional 2% per annum.

(v) The Company indirectly holds a 50% interest in NatuEra Colombia S.A.S. ("**NatuEra Colombia**") through the Company's joint venture, NatuEra S.à r.l. NatuEra Colombia is a wholly owned subsidiary of NatuEra S.à r.l., incorporated in Colombia. Advances are denominated in United States dollars ("**USD**"). \$302 (\$226 USD) (December 31, 2018 - \$nil) is governed by an unsecured promissory note bearing interest at a rate of 1% per annum. The loan is due January 25, 2020.

**7. Other investments**

Other investments consist of investments in common shares and warrants of companies in the cannabis industry. These investments, with the exception of shares of Evergreen Medicinal Supply Inc. ("**Evergreen**") and warrants of ABcann Global Corporation (now known as "**VIVO Cannabis Inc.**") ("**ABcann**"), were quoted in an active market as of the relevant period end date and, as a result, had a reliably measurable fair value as of such period end dates.

	As at March 31, 2019	As at December 31, 2018
Fair value through other comprehensive income investments		
Canopy Growth Corporation (" <b>Canopy</b> ") <sup>(i)</sup>	\$ -	\$ 405
Evergreen <sup>(iii)</sup>	300	300
	<u>\$ 300</u>	<u>\$ 705</u>
	Three Months Ended March 31, 2019	2018
Gain recognized in net income (loss)		
Aurora <sup>(iii)</sup>	\$ 924	\$ -
ABcann - share warrants <sup>(iv)</sup>	-	221
	<u>\$ 924</u>	<u>\$ 221</u>
	Three Months Ended March 31, 2019	2018
Gain (loss) recognized in other comprehensive income (loss) before taxes		
Canopy <sup>(i)</sup>	\$ 67	\$ 182
ABcann - shares <sup>(iv)</sup>	-	(190)
	<u>\$ 67</u>	<u>\$ (8)</u>

**7. Other investments (continued)**

- (i) During the three months ended March 31, 2019, the Company sold all remaining 11,062 common shares of Canopy for gross proceeds of \$472 (2018 - 18,436 shares for gross proceeds of \$687).
- (ii) On March 16, 2017, Evergreen received a cultivation license under the Cannabis Act. As a result, the Company completed its subscription for a second tranche of common shares of Evergreen for \$100 and exercised its option to acquire an additional 5% of the equity of Evergreen for \$500, for a total additional investment of \$600. However, Evergreen, through its counsel, has indicated that the Company is not entitled to any interest in Evergreen and has rejected the payment. The Company filed a statement of claim in the Supreme Court of British Columbia and Evergreen has filed a statement of defence. The Company intends to vigorously pursue the enforcement of its rights to acquire equity in Evergreen.
- (iii) In connection with the Whistler Transaction described in Note 6, the Company received 2,524,341 common shares of Aurora. During the three months ended March 31, 2019, the Company sold all 2,524,341 common shares of Aurora, for gross proceeds of \$25,606.
- (iv) During the three months ended March 31, 2018, the Company exercised 182,927 share warrants for aggregate consideration of \$113, for additional common shares of ABCann. Prior to the exercise, the share warrants were revalued to fair value using the Black-Scholes option pricing model. These ABCann shares were revalued to their fair value at the end of the period.

**8. Property, plant and equipment**

Cost	As at			As at	
	January 1, 2019	Additions <sup>(i)</sup>	Transfers	March 31, 2019	
Land	\$ 3,207	\$ 28	\$ -	\$ 3,235	
Building structures	21,652	9,394	106,766	137,812	
Furniture and equipment	676	143	-	819	
Computer equipment	464	227	-	691	
Security equipment	985	117	-	1,102	
Production equipment	4,823	222	-	5,045	
Road	137	-	-	137	
Leasehold improvements	1,584	165	-	1,749	
Construction in progress	141,473	3,665	(106,766)	38,372	
	<u>\$ 175,001</u>	<u>\$ 13,961</u>	<u>\$ -</u>	<u>\$ 188,962</u>	

Accumulated depreciation	As at			As at	
	January 1, 2019	Additions <sup>(i)</sup>	Transfers	March 31, 2019	
Building structures	\$ 1,184	\$ 745	\$ -	\$ 1,929	
Furniture and equipment	121	35	-	156	
Computer equipment	169	53	-	222	
Security equipment	384	54	-	438	
Production equipment	896	173	-	1,069	
Road	17	1	-	18	
Leasehold improvements	510	50	-	560	
	<u>\$ 3,281</u>	<u>\$ 1,111</u>	<u>\$ -</u>	<u>\$ 4,392</u>	
<b>Net book value</b>	<u>\$ 171,720</u>			<u>\$ 184,570</u>	

**8. Property, plant and equipment (continued)**

Cost	As at	Additions <sup>(i)</sup>	Transfers	As at
	January 1, 2018			March 31, 2018
Land	\$ 1,558	\$ 19	\$ -	\$ 1,577
Building structures	11,518	1,134	-	12,652
Furniture and equipment	134	229	-	363
Computer equipment	148	57	-	205
Security equipment	886	10	-	896
Production equipment	2,481	181	-	2,662
Road	137	-	-	137
Leasehold improvements	1,497	49	-	1,546
Construction in progress	39,337	6,186	-	45,523
	<u>\$ 57,696</u>	<u>\$ 7,865</u>	<u>\$ -</u>	<u>\$ 65,561</u>
Accumulated depreciation	As at	Additions <sup>(ii)</sup>	Transfers	As at
	January 1, 2018			March 31, 2018
Building structures	\$ 433	\$ 152	\$ -	\$ 585
Furniture and equipment	43	13	-	56
Computer equipment	75	13	-	88
Security equipment	196	45	-	241
Production equipment	431	104	-	535
Road	10	1	-	11
Leasehold improvements	336	41	-	377
	<u>\$ 1,524</u>	<u>\$ 369</u>	<u>\$ -</u>	<u>\$ 1,893</u>
<b>Net book value</b>	<u>\$ 56,172</u>			<u>\$ 63,668</u>

<sup>(i)</sup> During the three months ended March 31, 2019, there were non-cash additions from the amortization of capitalized transaction costs and the capitalization of accrued interest to construction in progress and building structures amounting to \$481 (2018 - \$223). Refer to Note 12. In addition, advances from non-controlling interests accrued interest of \$26 (2018 - \$nil) which was capitalized to construction in progress during the three months ended March 31, 2019. Refer to Note 10.

<sup>(ii)</sup> During the three months ended March 31, 2019, \$3 (2018 - \$nil) of the current period's depreciation expense was recorded as part of cost of sales. An additional \$892 (2018 - \$255) of depreciation expense was capitalized to biological assets and inventory.

**9. Intangible assets and goodwill**

## (a) Intangible assets

Cost	As at	Additions	As at
	January 1, 2019		March 31, 2019
Software	\$ 360	\$ 51	\$ 411
Health Canada Licenses - OGBC	1,611	-	1,611
Health Canada Licenses - Peace Naturals	9,596	-	9,596
Israeli Cannabis Code - Cronos Israel G.S. Cultivations Ltd. <sup>(i)</sup>	156	-	156
Israeli Cannabis Code - Cronos Israel G.S. Manufacturing Ltd. <sup>(i)</sup>	218	-	218
	<u>\$ 11,941</u>	<u>\$ 51</u>	<u>\$ 11,992</u>

<sup>(i)</sup> The Israeli Cannabis Codes were transferred by non-controlling interests to Cronos Israel in exchange for their equity interests in the Cronos Israel entities specified above. Refer to Note 10. The corresponding facilities are currently under construction. Amortization will begin when the facilities are available for use.

Accumulated amortization	As at	Additions	As at
	January 1, 2019		March 31, 2019
Software	\$ 73	\$ 40	\$ 113
Health Canada Licenses - OGBC	101	25	126
Health Canada Licenses - Peace Naturals	533	133	666
	<u>\$ 707</u>	<u>\$ 198</u>	<u>\$ 905</u>
<b>Net book value</b>	<u>\$ 11,234</u>		<u>\$ 11,087</u>

Cost	As at	Additions	As at
	January 1, 2018		March 31, 2018
Software	\$ -	\$ 131	\$ 131
Health Canada Licenses - OGBC	1,611	-	1,611
Health Canada Licenses - Peace Naturals	9,596	-	9,596
	<u>\$ 11,207</u>	<u>\$ 131</u>	<u>\$ 11,338</u>

Accumulated amortization	As at	Additions	As at
	January 1, 2018		March 31, 2018
Software	\$ -	\$ 8	\$ 8
Health Canada Licenses - OGBC	-	20	20
Health Canada Licenses - Peace Naturals	-	120	120
	<u>\$ -</u>	<u>\$ 148</u>	<u>\$ 148</u>
<b>Net book value</b>	<u>\$ 11,207</u>		<u>\$ 11,190</u>

**9. Intangible assets and goodwill (continued)**

## (b) Goodwill

	As at January 1, 2019	Additions	As at March 31, 2019
OGBC	\$ 392	\$ -	\$ 392
Peace Naturals	1,400	-	1,400
	<u>\$ 1,792</u>	<u>\$ -</u>	<u>\$ 1,792</u>

	As at January 1, 2018	Additions	As at March 31, 2018
OGBC	\$ 392	\$ -	\$ 392
Peace Naturals	1,400	-	1,400
	<u>\$ 1,792</u>	<u>\$ -</u>	<u>\$ 1,792</u>

**10. Subsidiaries with non-controlling interests**

In September 2018, the Company subscribed for its equity interest in a strategic joint venture in Israel, consisting of four legal entities, with the Israeli agricultural collective settlement Kibbutz Gan Shmuel ("**Gan Shmuel**"), for the production, manufacturing and distribution of medical cannabis. The Company's equity interest subscription in all four of the Israeli entities comprising Cronos Israel, was accounted for as an asset acquisition as the Israeli entities did not meet the definition of a business at the respective dates Cronos Group acquired control. During the three months ended March 31, 2018, the Company advanced \$926 to Cronos Israel under a promissory note, reflected in cash used in the Company's investing activities. As at March 31, 2019 and December 31, 2018, Cronos Israel has been included in these consolidated financial statements.

Financial information of significant subsidiaries with non-controlling interests are as follows:

	Cronos Israel G.S. Cultivations Ltd.	Cronos Israel G.S. Manufacturing Ltd.	As at March 31, 2019	As at December 31, 2018
Percentage interest held by non-controlling interests	30%	10%		
Current assets	\$ 786	\$ 802	\$ 1,588	\$ 1,403
Non-current assets	6,189	10,772	16,961	11,050
Current liabilities	963	228	1,191	401
Non-current liabilities <sup>(i)</sup>	6,450	10,074	16,524	10,601
Shareholders' equity	(438)	1,272	834	1,451
Attributable to:				
Cronos Group	(307)	1,145	838	1,315
Non-controlling interests	(131)	127	(4)	136

<sup>(i)</sup> Non-current liabilities include advances from non-controlling interests, in the amount of \$2,176 (December 31, 2018 - \$2,092) plus cumulative accrued interest of \$71 (December 31, 2018 - \$44). These advances are denominated in Israeli Shekels ("**ILS**"), are unsecured, bear interest at 5%, and have no fixed terms of repayment. Refer to Note 22(d).

The above information represents amounts before intercompany eliminations.

**11. Leases**

Information about leases for which the Company is a lessee is presented below.

**(a) Right-of-use assets**

The Company's leasing activities include the lease of land-use rights, office premises, and equipment used in the production of cannabis and related products.

<b>Cost</b>	<b>As at January 1, 2019 (Note 3)</b>	<b>Foreign exchange translation</b>	<b>As at March 31, 2019</b>
Land-use rights	\$ 884	\$ 14	\$ 898
Building	1,006	-	1,006
Production equipment	217	-	217
	<u>\$ 2,107</u>	<u>\$ 14</u>	<u>\$ 2,121</u>
<b>Accumulated depreciation</b>	<b>As at January 1, 2019 (Note 3)</b>	<b>Additions</b>	<b>As at March 31, 2019</b>
Land-use rights	\$ 40	\$ 15	\$ 55
Building	104	33	137
Production equipment	46	8	54
	<u>\$ 190</u>	<u>\$ 56</u>	<u>\$ 246</u>
<b>Net book value</b>	<u>\$ 1,917</u>		<u>\$ 1,875</u>
<b>Production equipment</b>	<b>As at January 1, 2018</b>	<b>Additions</b>	<b>As at March 31, 2018</b>
Cost	\$ -	\$ 217	\$ 217
Accumulated depreciation	-	(23)	(23)
<b>Net book value</b>	<u>\$ -</u>	<u>\$ 194</u>	<u>\$ 194</u>

**(b) Maturity analysis of lease obligations**

The following represents a maturity analysis of the Company's undiscounted contractual lease obligations and potential exposures as at March 31, 2019.

	<b>Less than one year</b>	<b>One to five years</b>	<b>More than five years</b>	<b>Total</b>
<b>Contractual obligations</b>				
Lease obligations recognized	\$ 379	\$ 1,350	\$ 1,766	\$ 3,495
Short-term leases not recognized <sup>(i)</sup>	351	-	-	351
	<u>730</u>	<u>1,350</u>	<u>1,766</u>	<u>3,846</u>
<b>Potential exposures</b>				
Extension options	-	-	4,049	4,049
Lease not yet commenced to which the Company is committed	98	1,211	827	2,136
	<u>\$ 828</u>	<u>\$ 2,561</u>	<u>\$ 6,642</u>	<u>\$ 10,031</u>

<sup>(i)</sup> The Company has applied the recognition exemption to short-term leases, which are therefore not recognized in the amended and restated unaudited condensed interim consolidated statements of financial position.

**11. Leases (continued)**

## (c) Supplemental disclosure

For the three months ended March 31, 2019, the Company recognized \$15 of interest expense on lease obligations and \$117 of lease payments associated with short-term leases in the amended and restated unaudited condensed interim consolidated statements of operations and comprehensive income (loss). For the three months ended March 31, 2019, the total cash outflow relating to leases amounted to \$164.

**12. Construction loan payable**

	As at March 31, 2019	As at December 31, 2018
Aggregate advances	\$ -	\$ 21,311
Less: transaction costs (net of amortization)	-	(481)
Add: accrued interest	-	121
	<u>\$ -</u>	<u>\$ 20,951</u>

On August 23, 2017, Peace Naturals, as borrower, signed a construction loan agreement with Romspen Investment Corporation as lender, to borrow \$40,000, to be funded by way of multiple advances. The aggregate advances were limited to \$35,000 until the lender received an appraisal valuing the property in British Columbia at an amount of not less than \$8,000. The loan bore interest at a rate of 12% per annum, calculated and compounded monthly, in arrears, on the amounts advanced from the date of each advance. The term of the loan was two years, with the borrower's option to extend for another twelve months. The loan was guaranteed by Cronos Group, Hortican, OGBC, the responsible-person-in-charge and the senior-person-in-charge of OGBC and Peace Naturals.

On January 23, 2019, the Company entered into a credit agreement with Canadian Imperial Bank of Commerce, as administrative agent and lender, and the Bank of Montreal, as lender, in respect of a \$65,000 secured non-revolving term loan credit facility (the "**Credit Facility**"). The Company used the funds available under the Credit Facility to fully repay the construction loan payable, consisting of \$21,311 in loan principal and \$275 in accrued interest and fees, calculated for the period from January 1, 2019 to January 22, 2019. On March 8, 2019, the Credit Facility was fully repaid. In connection to the Credit Facility, the Company incurred financing costs of \$523 which were expensed upon repayment of the Credit Facility.

**13. Derivative liabilities**

On March 8, 2019, the Company closed the previously announced investment in the Company (the "**Altria Investment**") by Altria Group, Inc. ("**Altria**"), pursuant to a subscription agreement dated December 7, 2018. The Altria Investment consists of 149,831,154 common shares of the Company, refer to Note 14(a), and one warrant of the Company (the "**Altria Warrant**"), refer to Note 13(a), issued to a wholly owned subsidiary of Altria. As of the closing date, Altria beneficially held an approximate 45% ownership interest in the Company (calculated on a non-diluted basis). As summarized in this note, if exercised in full on such date, the exercise of the Altria Warrant would result in Altria holding a total ownership interest in the Company of approximately 55% (calculated on a non-diluted basis). Pursuant to the investor rights agreement between the Company and Altria, entered into in connection with the closing of the Altria Investment (the "**Agreement**"), the Company granted Altria certain rights, among others, summarized in this note.

---

### 13. Derivative liabilities (continued)

The summaries below are qualified entirely by the terms and conditions fully set out in the Agreement and the Altria Warrant, as applicable.

- (a) The Altria Warrant entitles the holder, subject to certain qualifications and limitations, to subscribe for and purchase up to 73,990,693 common shares at the exercise price of \$19.00 per common share, until expiry on March 8, 2023. The number of common shares of the Company to which the holder is entitled, and the corresponding exercise price, is subject to adjustment pursuant to a share dividend, share issuance, distribution, or share subdivision, split or other division, share consolidation, reverse-split or other aggregation, share reclassification, a capital reorganization, consolidation, amalgamation, arrangement, binding share exchange, merger or other combination, certain securities issuances, redemptions or certain other actions that would result in a reduction in the number of common shares of the Company outstanding, in each case, executed by the Company. If and whenever there is a reclassification of the common shares or a capital reorganization of the Company, or a consolidation, amalgamation, arrangement, binding share exchange or merger of the Company, in each case executed by the Company and pursuant to which (i) in the event the consideration received by the Company's shareholders is exclusively cash, the Company or the successor entity is required to purchase the Altria Warrant in cash equal to the amount by which the purchase price per share paid for the common shares acquired exceeds the exercise price of the Altria Warrant multiplied by the number of common shares that would be issuable upon exercise of the Altria Warrant, and (ii) in the event the consideration received by the Company's shareholders is not exclusively cash, the Altria Warrant shall remain outstanding in accordance with its terms.
- (b) The Company granted to Altria, subject to certain qualifications and limitations, upon the occurrence of certain issuances of common shares of the Company executed by the Company (including issuances pursuant to the research and development partnership with Ginkgo Bioworks Inc. (the "**Ginkgo Agreement**")), refer to Note 19(a)(i)), the right to purchase up to such number of common shares of the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any shares so issued by the Company ("**Pre-emptive Rights**"), at the same price per common share of the Company at which the common shares of the Company are sold in the relevant issuance; provided that the price per common share of the Company to be paid pursuant to its exercise of its Pre-emptive Rights related to the Ginkgo Agreement will be \$16.25 per common share of the Company. These rights may not be exercised if Altria's ownership percentage of the issued and outstanding shares of the Company falls below 20%.
- (c) In addition to (and without duplication of) the Pre-emptive Rights, the Company granted to Altria, subject to certain qualifications and limitations, the right to subscribe for common shares of the Company issuable in connection with the exercise, conversion or exchange of convertible securities of the Company issued prior to March 8, 2019 or thereafter, a share incentive plan of the Company, the exercise of any right granted by the Company pro rata to all shareholders of the Company to purchase additional common shares and/or securities of the Company, bona fide bank debt, equipment financing or non-equity interim financing transactions that contemplates an equity component or bona fide acquisitions, mergers or similar business combination transactions or joint ventures involving the Company in order to maintain their ownership percentage of issued and outstanding common shares of the Company immediately preceding any such transactions ("**Top-up Rights**"). The price per common share to be paid by Altria pursuant to the exercise of its Top-up Rights will be, subject to certain limited exceptions, the 10-day volume-weighted average price of the common shares of the Company on the TSX at the time of exercise; provided that the per price per common share of the Company to be paid by Altria pursuant to the exercise of its Top-up Rights in connection with the issuance of common shares of the Company pursuant to the exercise of options or warrants that are outstanding as of March 8, 2019 will be \$16.25 per common share. These rights may not be exercised if Altria's ownership percentage of the issued and outstanding shares of the Company falls below 20%.

The Company's policy for accounting for its derivative liabilities is as follows:

Derivative liabilities are initially recognized at fair value at the date on which the derivative contract is entered into. Any attributable transaction costs are recognized in net income (loss) as incurred. Subsequent to initial recognition, derivative liabilities are measured at fair value, and changes are recognized immediately in net income (loss).



**13. Derivative liabilities (continued)**

The Altria Warrant, Pre-emptive Rights, and fixed price Top-up Rights have been classified as derivative liabilities; related transaction costs of \$29,038 have been expensed as financing costs. A reconciliation of the carrying amounts from the date of initial recognition, March 8, 2019, to March 31, 2019 is presented below:

	As at March 8, 2019	Gain on revaluation	As at March 31, 2019
(a) Altria Warrant	\$ 1,458,366	\$ (298,510)	\$ 1,159,856
(b) Pre-emptive Rights	124,176	(27,792)	96,384
(c) Top-up Rights	518,116	(110,081)	408,035
	<u>\$ 2,100,658</u>	<u>\$ (436,383)</u>	<u>\$ 1,664,275</u>

The fair values of the derivative liabilities were determined using the Black-Scholes pricing model as at March 8, 2019 and March 31, 2019, applying the following inputs:

	As at March 8, 2019			As at March 31, 2019		
	Altria Warrant	Pre-emptive Rights	Top-up Rights	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at grant date (per share)	\$29.15	\$29.15	\$29.15	\$24.55	\$24.55	\$24.55
Subscription price (per share)	\$19.00	\$16.25	\$16.25	\$19.00	\$16.25	\$16.25
(i) Weighted average risk-free interest rate	1.65%	1.64%	1.64%	1.53%	1.54%	1.53%
(ii) Weighted average expected life (in years)	4.00	2.00	2.68	3.94	2.00	2.68
(iii) Expected annualized volatility	80%	80%	80%	80%	80%	80%
Expected dividend yield	0%	0%	0%	0%	0%	0%

(i) The risk-free interest rate was based on Bank of Canada government treasury bills and bonds with a remaining term equal to the expected life of the derivative liabilities.

(ii) The expected life in years represents the period of time that the derivative liabilities are expected to be outstanding. The expected life of the Pre-emptive Rights and Top-up Rights is determined based on the expected term of the underlying options, warrants, and shares, to which the Pre-emptive Rights and Top-up Rights are linked.

(iii) Volatility was estimated by taking the average historical volatility of the Company and its peer group.

The following table quantifies each of the significant unobservable inputs described above and provides a sensitivity analysis of the impact on the reported values of the derivative liabilities. The sensitivity analysis for each significant input is performed by assuming a 10% decrease in the input while other significant inputs remain constant at management's best estimate as of the respective dates. As at March 8, 2019, there would be an equal but opposite impact on share capital, refer to Note 14(a), and as at March 31, 2019, there would be an equal but opposite impact on net income (loss).

Unobservable inputs	Decrease as at March 8, 2019			Decrease as at March 31, 2019		
	Altria Warrant	Pre-emptive Rights	Top-up Rights	Altria Warrant	Pre-emptive Rights	Top-up Rights
Share price at grant date (per share)	\$ 185,292	\$ 17,688	\$ 69,922	\$ 151,052	\$ 14,243	\$ 56,714
Weighted average expected life	41,622	3,477	12,998	38,935	3,388	12,529
Expected annualized volatility	76,423	5,022	22,130	72,295	4,997	21,654

These inputs are level 3 on the fair value hierarchy, and are subject to volatility and several uncontrollable factors, which could significantly affect the fair value of these derivative liabilities in future periods.

**14. Share capital****(a) Common shares**

The Company is authorized to issue an unlimited number of no par value common shares.

The holders of the common shares are entitled to receive dividends which may be declared from time to time, and are entitled to one vote per share at shareholder meetings of the Company. All common shares are ranked equally with regards to the Company's residual assets.

During the three months ended March 31, 2019, the Company issued 149,831,154 common shares in connection with the Altria Investment. The total gross proceeds received by the Company were \$2,434,757, which was first allocated to the derivatives liabilities issued in connection with the Altria Investment, refer to Note 13, and the residual of \$334,099 was allocated to share capital. Pursuant to the Altria Investment, the Company incurred transaction costs of \$33,939, of which \$4,901 was allocated to share capital and \$29,038 to the derivative liabilities based on the relative values assigned to the respective components.

During the three months ended March 31, 2018, the Company issued 5,257,143 common shares for aggregate gross proceeds of \$46,000 through a bought deal offering.

**(b) Shares to be issued**

For the three months ended March 31, 2018, the Company received cash of \$961 for the exercise of options and warrants, for which common shares were not yet issued as of March 31, 2018. Refer to Note 15(a) and (b). There were no shares to be issued as of March 31, 2019.

**15. Share-based payments****(a) Warrants**

The following is a summary of the changes in warrants from January 1, 2019 to March 31, 2019:

	Weighted average exercise price	Number of warrants	Share-based reserve
Balance at January 1, 2019	\$ 0.26	25,457,623	\$ 1,548
Exercise of warrants	0.27	(4,390,961)	(703)
Balance at March 31, 2019	<u>\$ 0.25</u>	<u>21,066,662</u>	<u>\$ 845</u>

The following is a summary of the changes in warrants from January 1, 2018 to March 31, 2018:

	Weighted average exercise price	Number of warrants	Share-based reserve
Balance at January 1, 2018	\$ 0.24	38,654,654	\$ 3,364
Exercise of warrants	0.18	(6,972,479)	(686)
Expiry of warrants	0.08	(82,695)	-
Balance at March 31, 2018	<u>\$ 0.25</u>	<u>31,599,480</u>	<u>\$ 2,678</u>

**15. Share-based payments (continued)**

## (a) Warrants (continued)

As at March 31, 2019, the Company had outstanding warrants as follows:

Grant date	Expiry date	Number of warrants	Weighted average exercise price
October 8, 2015 - October 28, 2015	October 8, 2020 - October 28, 2020	2,976,610	\$ 0.31
May 13, 2016 - May 27, 2016	May 13, 2021 - May 27, 2021	18,090,052	0.25
		<u>21,066,662</u>	<u>\$ 0.25</u>

## (b) Stock options

## (i) Stock option plans

The Company had adopted an amended and restated stock option plan dated May 26, 2015 (the "**2015 Stock Option Plan**") which was approved by shareholders of the Company at the annual and general meeting of shareholders held on June 28, 2017. The 2015 Stock Option Plan allowed the Board to award options to purchase shares to certain directors, officers, key employees and service providers of the Company.

On June 28, 2018, the shareholders of the Company approved a new stock option plan (the "**2018 Stock Option Plan**") which superseded the 2015 Stock Option Plan. The 2018 Stock Option Plan was amended by the Board in May 2019 to provide for certain provisions relevant to the treatment of options that may be issued from time to time to participants resident in Israel, in order to reflect the requirements of certain Israeli tax laws. No further awards will be granted under the 2015 Stock Option Plan; however, shares may be purchased via option exercise by the holders of any outstanding stock options previously issued under the 2015 Stock Option Plan.

Participants under the 2018 Option Plan are eligible to be granted options to purchase shares at an exercise price established upon approval of the grant by the Board. When options are granted, the exercise price is, with respect to a particular date, the closing price as reported by the TSX on the immediately preceding trading day (the "**Fair Market Value**"). The 2018 Option Plan does not authorize grants of options with an exercise price below the Fair Market Value.

Vesting conditions for grants of options are determined by the Board. The typical vesting for employee grants is quarterly vesting over four to five years, and the typical vesting for directors and executive officers is quarterly vesting over three to five years. The term of the options is established by the Board, provided that the term of an option may not exceed seven years from the date of the grant.

The 2018 Option Plan also provides for the issuance of share appreciation rights ("**SARs**") in tandem with options. Each SAR entitles the holder to surrender to the Company, unexercised, the right to subscribe for shares pursuant to the related option and to receive from the Company a number of shares, rounded down to the next whole share, with a Fair Market Value on the date of exercise of each such SAR that is equal to the difference between such Fair Market Value and the exercise price under the related option, multiplied by the number of shares that cease to be available under the option as a result of the exercise of the SAR, subject to satisfaction of applicable withholding taxes and other source deductions. Each unexercised SAR terminates when the related option is exercised or the option terminates, including upon a change in control. Upon each exercise of a SAR, in respect of a share covered by an option, such option is cancelled and is of no further force or effect in respect of such share.

**15. Share-based payments (continued)**

## (ii) Summary of changes

The following is a summary of the changes in options from January 1, 2019 to March 31, 2019:

	Weighted average exercise price	Number of options	Share-based reserve
Balance at January 1, 2019	\$ 2.99	12,902,995	\$ 6,241
Issuance of options	24.75	51,830	-
Exercise of options and SARs	5.60	(125,715)	(347)
Cancellation of options	1.40	(2,500)	-
Vesting of issued options	-	-	737
Balance at March 31, 2019	<u>\$ 3.06</u>	<u>12,826,610</u>	<u>\$ 6,631</u>

The following is a summary of the changes in options from January 1, 2018 to March 31, 2018:

	Weighted average exercise price	Number of options	Share-based reserve
Balance at January 1, 2018	\$ 2.05	11,603,750	\$ 2,289
Issuance of options	8.61	430,000	-
Exercise of options	1.72	(42,256)	(33)
Vesting of issued options	-	-	774
Balance at March 31, 2018	<u>\$ 2.29</u>	<u>11,991,494</u>	<u>\$ 3,030</u>

The weighted average share price at the dates the options were exercised during the three months ended March 31, 2019 was \$26.12 per share (2018 - \$9.58 per share).

As at March 31, 2019, the Company had outstanding and exercisable options as follows:

Grant date	Vesting terms	Expiry date	Number of options	Weighted average	
				Exercise price	Remaining contractual life (in years)
August 5, 2016	Evenly over 48 months	August 5, 2021	1,058,334	\$ 0.50	2.35
October 6, 2016	Evenly over 48 months	October 6, 2021	3,366,372	1.23	2.52
November 21, 2016	Evenly over 48 months	November 21, 2021	182,000	1.84	2.65
April 12, 2017	Evenly over 48 months	April 12, 2022	3,269,258	3.14	3.04
August 23, 2017	Evenly over 48 months	August 23, 2022	2,869,649	2.42	3.40
November 9, 2017	Evenly over 48 months	November 9, 2022	200,000	3.32	3.61
January 30, 2018	Evenly over 48 months	January 30, 2023	272,917	8.40	3.84
January 31, 2018	Evenly over 48 months	January 31, 2023	109,375	9.00	3.84
May 18, 2018	Evenly over 48 months	May 18, 2023	1,163,750	7.57	4.13
June 28, 2018	Evenly over 20 quarters	June 28, 2023	180,000	8.22	4.25
September 13, 2018	Evenly over 16 quarters	September 13, 2025	25,000	14.70	6.46
October 12, 2018	Evenly over 16 quarters	October 12, 2025	28,125	11.80	6.54
December 14, 2018	Evenly over 20 quarters	December 14, 2025	50,000	15.29	6.71
March 28, 2019	Evenly over 16 quarters	March 28, 2024	51,830	24.75	5.00
Outstanding at March 31, 2019			<u>12,826,610</u>	<u>\$ 3.06</u>	<u>3.11</u>
Exercisable at March 31, 2019			<u>5,868,386</u>	<u>\$ 2.28</u>	<u>2.91</u>

**15. Share-based payments (continued)**

## (ii) Summary of changes (continued)

These options expire at the earlier of 180 days of the death, disability or incapacity of the holder or specified expiry date, and can only be settled in common shares.

As at March 31, 2019, the weighted average exercise price of options outstanding was \$3.06 per option (December 31, 2018 - \$2.99 per option). The weighted average exercise price of options exercisable was \$2.28 per option (December 31, 2018 - \$2.28 per option).

## (iii) Fair value of options issued

The fair value of the options issued during the period was determined using the Black-Scholes option pricing model, using the following inputs:

	<b>Three Months Ended March 31,</b>	
	<b>2019</b>	<b>2018</b>
Share price at grant date (per share)	\$24.75	\$8.40 - \$9.00
Exercise price (per option)	\$24.75	\$8.40 - \$9.00
<sup>(i)</sup> Risk-free interest rate	1.51%	2.01%
<sup>(ii)</sup> Expected life of options (in years)	5	5
<sup>(iii)</sup> Expected annualized volatility	80%	55%
Expected dividend yield	0%	0%
Weighted average Black-Scholes value at grant date (per option)	\$15.91	\$4.20

<sup>(i)</sup> The risk-free interest rate was based on Bank of Canada government bonds with a term equal to the expected life of the options.

<sup>(ii)</sup> The expected life in years represents the period of time that the options granted are expected to be outstanding.

<sup>(iii)</sup> Volatility was estimated by taking the average historical volatility of the Company and its peer group.

**16. Revenue from contracts with customers**

The Company derives revenue from the following major product lines and geographical regions:

	Three Months Ended March 31,	
	2019 (Restated - Note 27)	2018
<b>Canadian</b>		
Dry cannabis	\$ 2,851	\$ 2,420
Cannabis oils	1,527	255
Other	103	105
	<u>4,481</u>	<u>2,780</u>
<b>International</b>		
Dry cannabis	28	165
Total gross revenue from contracts with customers	<u>\$ 4,509</u>	<u>\$ 2,945</u>

During the three months ended March 31, 2019, the Company earned gross revenue of \$1,332 from 1 major customer (2018 - \$1,575 from 1 major customer). During the three months ended March 31, 2019, \$172 (2018 - \$nil) in expected credit losses were recognized on receivables from contracts with customers in net income (loss). Refer to Note 22(a)(i).

**17. Earnings (loss) per share**

Basic and diluted earnings (loss) per share are calculated using the following numerators and denominators:

	Three Months Ended March 31,	
	2019 (Restated - Note 27)	2018
<b>Basic earnings (loss) per share computation</b>		
Net income (loss) attributable to common shareholders of Cronos Group	\$ 428,104	\$ (1,050)
Weighted average number of common shares outstanding	218,949,590	157,054,891
Basic earnings (loss) per share	\$ 1.96	\$ (0.01)
<b>Diluted earnings (loss) per share computation</b>		
Net income (loss) used in the computation of basic earnings (loss) per share	\$ 428,104	\$ (1,050)
Adjustment for gain on revaluation of derivative liabilities	(298,786)	-
Net income (loss) used in the computation of diluted income (loss) per share	<u>\$ 129,318</u>	<u>\$ (1,050)</u>
Weighted average number of common shares outstanding used in the computation of basic earnings (loss) per share	218,949,590	157,054,891
Dilutive effect of warrants	23,294,663	-
Dilutive effect of stock options and share appreciation rights	11,351,671	-
Dilutive effect of Altria Warrant	17,472,990	-
Dilutive effect of Top-up Rights	17,661	-
Weighted average number of common shares outstanding used in the computation of diluted earnings (loss) per share	<u>271,086,575</u>	<u>157,054,891</u>
Diluted earnings (loss) per share	\$ 0.48	\$ (0.01)

**17. Earnings (loss) per share (continued)**

The following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because conditions for contingently issuable shares were not satisfied at the end of the reporting period.

	Notes	Three Months Ended March 31,	
		2019	2018
Ginkgo Equity Milestones	19(a)	14,674,903	-
Pre-emptive Rights	13(b)	12,006,739	-
Top-up Rights	13(c)	27,730,859	-
Warrants	15(a)	-	31,599,480
Stock options	15(b)	-	11,991,494
		<u>54,412,501</u>	<u>43,590,974</u>

**18. Related party transactions**

The following is a summary of the Company's related party transactions during the period:

## (a) Key management compensation

Key management personnel are persons responsible for planning, directing and controlling activities of the entity, and include executive and non-executive directors. Compensation provided to key management is as follows:

	Three Months Ended March 31,	
	2019	2018
Short-term employee benefits, including salaries and fees	\$ 104	\$ 109
Professional fees	96	58
Share-based payments	226	339
	<u>\$ 426</u>	<u>\$ 506</u>

During the three months ended March 31, 2019 and 2018, there were no options issued to key management. As at March 31, 2019 and December 31, 2018, there were no amounts owing to members of key management.

## (b) Director compensation

During the period ended March 31, 2019, there were no options (2018 - 150,000 options) issued to directors of the Company and share-based payments of \$214 (2018 - \$239) were recognized. Refer to Note 15(b).

---

**19. Commitments and contingencies**

- (a) The Company has committed funding to the following R&D projects:
- (i) *Ginkgo*. On September 4, 2018, the Company announced a research and development partnership with Ginkgo Bioworks Inc. ("**Ginkgo**") to develop scalable and consistent production of a wide range of cannabinoids, including THC, CBD and a variety of other lesser known and rarer cannabinoids. As part of this partnership, Cronos Group has agreed to issue up to 14,674,903 common shares of the Company (aggregate value of approximately \$100,000 USD as of July 17, 2018 assuming all milestones are met) ("**Ginkgo Equity Milestones**") in tranches and \$22,000 USD in cash subject to Ginkgo's achievement of certain milestones ("**Ginkgo Research and Development Milestones**") and to fund certain R&D expenses, including foundry access fees. From September 4, 2018 to March 31, 2019, the Company paid a total of \$2,000 USD in foundry access fees. Subsequent to March 31, 2019, the Company and Ginkgo agreed to the provision of certain development, scale up, and manufacturing services by Ginkgo to the Company related to deployment and commercialization of developed products, for approximately \$2,598 USD over the remaining current fiscal year. Subsequent to March 31, 2019, two Ginkgo Research and Development Milestones were achieved, refer to Note 25(a).
- (ii) *Technion*. On October 15, 2018, the Company announced a sponsored research agreement with the Technion Research and Development Foundation of the Technion – Israel Institute of Technology ("**Technion**"). Research will be focused on the use of cannabinoids and their role in regulating skin health and skin disorders. The Company has committed to \$1,784 USD of research funding over a period of three years. From October 9, 2018 to March 31, 2019, the Company paid a total of \$598 USD in research funding. An additional \$4,900 USD of cash payments will be paid to Technion upon the achievement of certain milestones.
- (b) *Altria Services*. On February 18, 2019, the Company entered into an agreement with Altria Ventures Inc. ("**Altria Ventures**"), a wholly-owned subsidiary of Altria, to receive strategic advisory and project management services from Altria Ventures (the "**Services Agreement**"). Pursuant to the Services Agreement, the Company will pay Altria Ventures a monthly fee equal to the product of one hundred and five percent (105%) and the sum of: (i) all costs directly associated with the services incurred during the monthly period, and (ii) a reasonable and appropriate allocation of indirect costs incurred during the monthly period. The Company will also pay all third party direct charges incurred during the monthly period in connection with the services, including any reasonable and documented costs, fees and expenses associated with obtaining any consent, license or permit. The Services Agreement will remain in effect until terminated by either party.
- (c) The following contingencies are related to Peace Naturals:
- (i) *MedCann Access Acquisition Claim*. On July 31, 2015, 8437718 Canada Inc., 8437726 Canada Inc., Michael Blaine Dowdle, Rade Kovacevic, Kevin Furet and 9388036 Canada Inc. (collectively, the "**Plaintiffs**") commenced a claim against Peace Naturals and a number of other parties, for \$15,000 in damages allegedly resulting from the termination of a share purchase transaction for the acquisition of the Plaintiffs' company, MedCann Access. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized. On February 21, 2018, the parties began the discovery phase of the proceedings, which is ongoing.
- (ii) *Warrants Claim*. Jeffrey Gobuty, brother to Mark Gobuty, former CEO of Peace Naturals, brought a claim against Peace Naturals for \$300 and for warrants valued at \$125 that were purportedly issued by Mark Gobuty, the former CEO of Peace Naturals. This matter remains in the early stages of litigation and has not yet advanced to the discovery phase. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized.
- (iii) *Former Employees' Unlawful Termination Claims*. Peace Naturals and Cronos Group were served with claims by Jennifer Caldwell, a former employee, for damages of \$580 and 30,000 options of the Company, in connection with claims of alleged wrongful termination. The Company believes that the allegations contained in the statement of claim are without merit and plans to vigorously defend itself; accordingly, no provision for loss has been recognized.



**19. Commitments and contingencies (continued)**

(d) The following contingencies were resolved during the three months ended March 31, 2019:

- (i) *U.S. Securities Class Action Claims.* Two purported shareholders of Cronos Group each filed a putative class action in the United States District Court for the Southern District of New York against the Company and its CEO, alleging that the Company's continuous disclosure omitted material information with respect to matters raised in a document published on a short-seller's website, thus rendering the Company's disclosure false and misleading in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder. The complaints purport to seek, among other things, compensatory damages and a reasonable allowance for plaintiff attorneys' and experts' fees. On January 28, 2019, the U.S. Securities Class Action Claims relating to Cronos Group and its CEO were voluntarily discontinued.
- (ii) *Former Employees' Unlawful Termination Claims.* Peace Naturals and Cronos Group were served with claims by Mark Gobuty, the former CEO of Peace Naturals, for approximately \$12,682 and a 10% equity interest in Peace Naturals, in connection with alleged claims of wrongful termination. On January 30, 2019, this claim was settled, with total settlement proceeds of \$644 payable to Mr. Gobuty and the claim was discontinued. This amount was released from the trust account on January 31, 2019.

**20. Income taxes**

The Company's combined Canadian federal and provincial statutory income tax rate is 26.5% for the periods ended March 31, 2019 and 2018. The rate is expected to apply for the full year. The effective tax rate differs from the statutory tax rate due to the non-taxable gain on revaluation of derivative liabilities. The Altria Warrant, Pre-emptive Rights and Top-up Rights would currently be settled through the issuance of shares of the Company, if exercised by Altria, which is not expected to result in a taxable gain or loss to the Company.

Deferred tax assets and liabilities have been offset where they relate to income taxes levied by the same taxation authority and the Company has the legal right and intent to offset. The changes in the net deferred tax liability are provided below:

	Three Months Ended March 31,	
	2019 (Restated - Note 27)	2018
Balance - beginning of period	\$ 1,850	\$ 1,416
Recognized in net income (loss)	2,182	(888)
Recognized in other comprehensive income (loss)	(36)	27
Balance - end of period	<u>\$ 3,996</u>	<u>\$ 555</u>

**21. Supplemental cash flow information**

(a) The net changes in non-cash working capital items are as follow:

	Notes	Three Months Ended March 31,	
		2019 (Restated - Note 27)	2018
Interest receivable		\$ (3,130)	\$ -
Accounts receivable		1,402	(1,386)
Sales taxes receivable		(1,821)	(1,152)
Prepaid expenses and other assets		(902)	(3,866)
Biological assets	4(b)	11,695	2,026
Inventory	4(b)	(15,814)	(2,756)
Accounts payable and other liabilities		26,596	(5,078)
Holdbacks payable		595	-
Government remittances payable		190	-
<b>Net changes in non-cash working capital</b>		<u>\$ 18,739</u>	<u>\$ (12,212)</u>

**21. Supplemental cash flow information (continued)**

(b) The reconciliation of the cash flows from derivative liabilities, refer to Note 13, is as follows:

Balance - beginning of period	\$	-
Cash flows from financing activities:		
Altria Warrant		1,458,366
Pre-emptive Rights		124,176
Top-up Rights		518,116
Non-cash changes:		
Gain on revaluation of derivative liabilities		(436,383)
Balance - end of period	<u>\$</u>	<u>1,664,275</u>

**22. Financial instruments**

(a) Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations. The Company is exposed to credit risk from its operating activities, primarily accounts receivable, and its investing activities, including cash and cash equivalents held with banks and financial institutions, interest receivable, and advances to joint ventures. The Company's maximum exposure to this risk is equal to the carrying amount of these financial assets.

(i) Accounts receivable

An impairment analysis is performed at each reporting date using a provision matrix to measure expected credit losses. The provision rates are based on the days past due for groupings of various customer segments with similar loss patterns. The calculation reflects the probability-weighted outcome, the time value of money, and reasonable and supportable information that is available at the reporting date about past events, current conditions and forecasts of future economic conditions. Accounts receivable are written off when there is no reasonable expectation of recovery. Indicators that there is no reasonable expectation of recovery include, amongst others, the failure of a debtor to engage in a repayment plan, and a failure to make contractual payments for a period of greater than 120 days past due. As at March 31, 2019, the Company recognized an approximate expected credit loss allowance of \$222 (December 31, 2018 - \$50).

Provided below is the information about the credit risk exposure on the Company's accounts receivable using a provision matrix of expected credit loss rates against an analysis of the age of accounts receivable:

	Expected credit loss rates	As at March 31, 2019 (Restated - Note 27)	As at December 31, 2018
Less than 30 days past billing date	0% to 3%	\$ 2,576	\$ 3,980
31 to 60 days past billing date	0% to 5%	100	136
61 to 90 days past billing date	0% to 8%	15	-
91 to 120 days past billing date	0% to 12%	-	19
Over 120 days past billing date	0% to 18%	70	28
		<u>\$ 2,761</u>	<u>\$ 4,163</u>

The Company has assessed that there is a concentration of credit risk; 51.0% of the Company's accounts receivable were due from 2 customers as at March 31, 2019 (December 31, 2018 - 87.6% due from 5 customers).

**22. Financial instruments (continued)****(a) Credit risk (continued)****(ii) Cash and cash equivalents and interest receivable**

The Company held cash and cash equivalents amounting to \$2,418,277 at March 31, 2019 (December 31, 2018 - \$32,634). The interest receivable of \$3,130 represents accrued interest recognized on cash equivalents as at March 31, 2019. The cash and cash equivalents are held with central banks and financial institution counterparties that are highly rated. Cash equivalents are highly liquid investments with a maturity of 90 days or less. As such, the Company has assessed an insignificant loss allowance on cash and cash equivalents and interest receivable.

**(iii) Advances to joint ventures**

The Company has assessed that there has been no significant increase in credit risk of these advances from initial recognition based on the financial position, as well as the regulatory and economic environment of the borrowers. As a result, the loss allowance recognized during the period was limited to 12 month expected credit losses. Based on historical information, and adjusted for forward-looking expectations, the Company has assessed an insignificant loss allowance on these advances as at March 31, 2019 and December 31, 2018.

**(b) Liquidity risk**

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due, and arises principally from the Company's bank indebtedness, accounts payable and other liabilities, holdbacks payable, government remittances payable, construction loan payable, derivative liabilities, lease obligations, and due to non-controlling interests. The Company's policy is to review liquidity resources and ensure that sufficient funds are available to meet financial obligations as they become due. Further, the Company's management is responsible for ensuring funds exist and are readily accessible to support business opportunities as they arise. The Company's funding is primarily provided in the form of capital raised through the issuance of shares and share-based instruments.

The following represents an analysis of the age of accounts payable:

	<b>As at March 31, 2019 (Restated - Note 27)</b>	<b>As at December 31, 2018</b>
Less than 30 days past billing date	\$ 30,619	\$ 1,201
31 to 60 days past billing date	3,847	365
61 to 90 days past billing date	75	29
Over 90 days past billing date	572	-
	<u>\$ 35,113</u>	<u>\$ 1,595</u>

As at March 31, 2019, 94% of the Company's payables were due to 2 vendors (December 31, 2018 - 35% due to 1 vendor).

**22. Financial instruments (continued)**

## (c) Market risk (price risk)

Price risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in market prices. The value of the financial instruments can be affected by changes in interest rates, market and economic conditions, and equity and commodity prices. The Company is exposed to price risk in divesting its investments, such that, unfavourable market conditions could result in dispositions of investments at less than favourable prices. Further, the revaluation of securities classified as fair value through other comprehensive income, could result in significant write-downs of the Company's investments, which would have an adverse impact on the Company's financial position.

The Company previously managed price risk by having a portfolio of securities from multiple issuers, such that the Company was not singularly exposed to any one issuer. During the three months ended March 31, 2019, the Company substantially divested from its investments subject to price risk. Refer to Note 7.

## (d) Currency risk

Currency risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will significantly fluctuate due to changes in foreign exchange rates. The Company is exposed to this risk on advances to joint ventures denominated in AUD and USD, refer to Note 6(a). The Company is further exposed to this risk through subsidiaries operating in Israel, refer to Note 2(d). The Company does not currently use foreign exchange contracts to hedge its exposure to currency risk as management has determined that this risk is not significant at this point in time. As such, the Company's financial position and financial results may be adversely affected by the unfavourable fluctuations in currency exchange rates.

The following table provides a summary of financial instruments denominated in foreign currency (in thousands):

	Currency	As at March 31, 2019	As at December 31, 2018
Advances to joint venture	AUD	1,561	1,029
Advances to joint venture	USD	226	-
Cash	ILS	1,798	840
Sales taxes receivable	ILS	2,492	2,066
Bank indebtedness	ILS	1,141	-
Accounts payable and other liabilities	ILS	1,985	1,083
Due to non-controlling interests	ILS	6,080	5,878
Lease obligations (including current portion)	ILS	2,374	-

A 10% strengthening of the Canadian dollar against the foreign currencies listed above would decrease net income by \$162 and increase other comprehensive income by \$245 (December 31, 2018 - increase net loss by \$90 and decrease other comprehensive income by \$326). A 10% weakening of the Canadian dollar against the foreign currencies listed above would result in an equal, but opposite effect.

## (e) Interest rate risk

The Company's exposure to interest rate risk only relates to any investments of surplus cash. The Company invests surplus cash in highly liquid investments with short terms to maturity that would accumulate interest at prevailing rates for such investments. As at March 31, 2019, the Company had cash and cash equivalents amounting to \$2,418,277 (December 31, 2018 - \$32,634).

---

### 23. Fair value hierarchy

Assets recorded at fair value on the amended and restated unaudited condensed interim consolidated statements of financial position are classified using a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - valuation based on quoted prices (unadjusted) in active markets for identical assets and liabilities. In these amended and restated unaudited condensed interim consolidated financial statements, other investments (Canopy) are included in this category.

Level 2 - valuation techniques based on inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. In these amended and restated unaudited condensed interim consolidated financial statements, there are no financial instruments included in this category.

Level 3 - valuation techniques using the inputs for the asset or liability that are not based on observable market data. In these amended and restated unaudited condensed interim consolidated financial statements, other investments (Evergreen), biological assets, and derivative liabilities are included in this category.

The Company's policy for determining when transfers between levels of the fair value hierarchy occur is based on the date of the event or changes in circumstances that caused the transfer. For the three months ended March 31, 2019 and 2018, there were no transfers between levels.

For all financial instruments classified as amortized cost, the carrying value approximated fair value at the reporting dates.

### 24. Capital management

The Company's objectives when managing its capital are to maintain a sufficient capital base to: (i) meet its short-term obligations, (ii) sustain future operations and expansions, (iii) ensure its ability to continue as a going concern, and (iv) retain stakeholder confidence. The Company defines capital as its net assets, total assets less total liabilities. The Company manages its capital structure and adjusts it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust its capital structure, the Company may issue new shares, options, or warrants, issue new debt, or acquire or dispose of assets. The Company is not subject to externally imposed capital requirements. Management reviews its capital management approach on an ongoing basis and believes that this approach is reasonable. There have been no changes to the Company's capital management approach in the period.

As at March 31, 2019, the Company managed net assets of \$970,225 (December 31, 2018 - \$211,640).

### 25. Non-monetary transaction

On March 28, 2019, the Company entered into two transactions to simultaneously purchase and sell inventory to a third party. The Company purchased cannabis resin and in turn sold cannabis dry flower the third party. The transactions involved the exchange of work in progress inventory and were accounted for at the carrying value of inventory transferred by the Company which equaled the value of the cannabis resin received. No revenue was recognized as a result of this transaction and no gain or loss was recognized in the Amended and Restated Unaudited Consolidated Statements of Operations and Comprehensive Income (Loss).

### 26. Subsequent events

- (a) On April 9 and 10, 2019, two Ginkgo Research and Development Milestones were reached, respectively, and the Company made cash payments amounting to \$650 USD. These milestone achievement payments are in addition to the quarterly \$1,000 USD foundry access fees. Refer to Note 19(a)(i).
- (b) On April 15, 2019, the Company, through Cronos Device Labs, purchased certain assets from a wholly owned subsidiary of Altria, for approximately \$1,625 (4,345 ILS) in cash.
- (c) Subsequent to March 31, 2019, a total of 89,247 share appreciation rights were exercised, in lieu of the associated options, in exchange for 62,524 common shares. Also, subsequent to March 31, 2019, a total of 4,950 options were exercised for \$15 in cash. These share appreciation right and stock option exercises had a weighted average exercise price of \$1.39 per common share.
- (d) Subsequent to March 31, 2019, a total of 1,000,000 warrants were exercised in exchange for \$245 in cash. These warrants had a weighted average exercise price of \$0.25 per common share.

**27. Restatement**

The Company has amended and restated its unaudited condensed interim consolidated financial statements for the three months ended March 31, 2019 (“**interim financial statements**”). Subsequent to the original issuance of the interim financial statements, the Audit Committee of the Company’s Board of Directors, with the assistance of outside counsel and forensic accountants, conducted a review of certain bulk resin purchases and sales of products through the wholesale channel and the appropriateness of the recognition of the revenue associated with those transactions. As a result of this review, it was concluded that there were accounting errors in the previously filed interim financial statements. In the case of the three months ended March 31, 2019, these accounting errors were due to one wholesale transaction that was inappropriately accounted for as revenue. The transaction involved the exchange of cannabis dry flower for cannabis resin, with a third party, in two simultaneous transactions entered into in contemplation of one another. Subsequent to the original issuance of the interim financial statements, this transaction was not deemed to meet the criteria for revenue recognition in accordance with IFRS 15 and was subsequently accounted for as a non-monetary transaction valued at the carrying value of the inventory exchanged. This resulted in revenue being overstated by approximately \$2.5 million and cost of goods sold being overstated by approximately \$2.4 million on the Consolidated Statements of Operations and Comprehensive Income (Loss), in each case in the interim financial statements for the three months ended March 31, 2019. Refer to note 25. The resulting corrections are noted in the adjustments column in the following tables.

Restated line items on the Amended and Restated Unaudited Condensed Interim Consolidated Statements of Financial Position:

	As at March 31, 2019		
	As previously reported	Adjustments	Restated
<b>Assets</b>			
Accounts receivable	\$ 5,559	\$ (2,798)	\$ 2,761
Sales taxes receivable	5,594	(354)	5,240
Inventory	25,150	(68)	25,082
Total current assets	2,474,308	(3,220)	2,471,088
Total assets	2,698,037	(3,220)	2,694,817
<b>Liabilities</b>			
Accounts payable and other liabilities	45,016	(3,120)	41,896
Total current liabilities	1,719,642	(3,120)	1,716,522
Deferred income tax liability	4,371	(375)	3,996
Total liabilities	1,728,087	(3,495)	1,724,592
<b>Shareholders' equity (deficit)</b>			
Retained earnings (accumulated deficit)	404,499	275	404,774
Total equity attributable to shareholders of Cronos Group	969,954	275	970,229
Total shareholders' equity	969,950	275	970,225

Restated line items on the Amended and Restated Unaudited Condensed Interim Consolidated Statements of Operations and Comprehensive Income (Loss):

	Three months ended March 31, 2019		
	As previously reported	Adjustments	Restated
Gross Revenue	\$ 6,895	\$ (2,476)	\$ 4,509
Cost of sales before fair value adjustments	2,984	(1,057)	1,927
Gross profit before fair value adjustments	3,486	(1,419)	2,067
Realized fair value adjustments on inventory sold in the period	3,722	(1,319)	2,403
Gross profit	13,317	(100)	13,217
Deferred income tax expense (recovery)	2,557	(375)	2,182
Net income (loss)	427,693	275	427,968
Comprehensive income (loss)	427,812	275	428,087
<b>Earnings (loss) per share</b>			
Basic	1.95	0.01	1.96
Diluted	0.48	-	0.48

**27. Restatement (continued)**

Restated line items on the Amended and Restated Unaudited Condensed Interim Consolidated Statements of Changes in Equity:

	As at March 31, 2019		
	Previously reported	Adjustments	Restated
Retained earnings (accumulated deficit) as at January 31, 2019	\$ (22,783)	\$ —	\$ (22,783)
Net income (loss) for three months ended March 31, 2019	427,829	275	428,104
Retained earnings (accumulated deficit) as at March 31, 2019 <sup>(i)</sup>	404,499	275	404,774

<sup>(i)</sup> Adjustment in retained earnings (accumulated deficit) as at June 30, 2019 due to net income change stated above.

Restated line items on the Amended and Restated Unaudited Condensed Interim Consolidated Statements of Cash Flows:

	Three months ended March 31, 2019		
	As previously reported	Adjustments	As restated
<b>Operating activities</b>			
Net income (loss)	\$ 427,693	\$ 275	\$ 427,968
Realized fair value adjustment on inventory sold in the period	3,722	(1,319)	2,403
Deferred income tax expense (recovery)	2,557	(375)	2,182
Net changes in non-working capital	17,320	1,419	18,739
Cash and cash equivalents used in operating activities	(18,401)	-	(18,401)